Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria
Clinical & Experimental Allergy · 2023
DOI: 10.1111/cea.14402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2023. Verfasst von Katrine Baumann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Urticaria Center of Reference and Excellence (UCARE), Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denm…. Hauptthemen laut MEDLINE: Chronic Urticaria, Anti-Allergic Agents, Urticaria. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Fonden.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Urticaria Center of Reference and Excellence (UCARE), Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark.
- RefLab ApS, Copenhagen, Denmark.
- LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
- Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark.
- Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
ORCID-Profile: Katrine Baumann, Ditte Georgina Zhang, Misbah Noshela Ghazanfar, Marcus Maurer
Förderung
- Novo Nordisk Fonden
Zitieren
APA
Baumann, K., Jørgensen, A. R., Sørensen, J. A., Zhang, D. G., Ghazanfar, M. N., Skov, P. S., Woetmann, A., Vestergaard, C., Maurer, M., & Thomsen, S. F. (2023). Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14402
Vancouver
Baumann K, Jørgensen AR, Sørensen JA, Zhang DG, Ghazanfar MN, Skov PS, et al. Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. 2023. doi:10.1111/cea.14402
BibTeX
@article{Baumann2023,
author = {Baumann, Katrine and Jørgensen, Astrid-Helene Ravn and Sørensen, Jennifer Astrup and Zhang, Ditte Georgina and Ghazanfar, Misbah Noshela and Skov, Per Stahl and Woetmann, Anders and Vestergaard, Christian and Maurer, Marcus and Thomsen, Simon Francis},
title = {Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria},
journal = {Clinical & Experimental Allergy},
year = {2023},
doi = {10.1111/cea.14402}
}
EUVIMED